This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by GOLAY, A. Articles by CHEN, Y.-D. I. Search for Related Content PubMed PubMed Citation Articles by GOLAY, A. Articles by CHEN, Y.-D. I.

High Density Lipoprotein (HDL) Metabolism in Noninsulin-Dependent Diabetes Mellitus: Measurement of HDL Turnover Using Tritiated HDL^*

A. GOLAY, L. ZECH, M.-Z. SHI, Y.-A. M. CHIOU, G. M. REAVEN and Y.-D. I. CHEN

Department of Medicine, Stanford University School of Medicine Stanford, California 94305
Department of Health and Human Service, Public Health Service, National Heart Lung and Blood Institute, National Institutes of Health (L.Z.) Bethesda, Maryland 20205

Address all correspondence and requests for reprints to: Ida Chen, Ph.D., Department of Medicine S-005, Stanford University Medical Center, Stanford, California 94305.

High density lipoprotein (HDL) kinetics were studied by injecting [³H]apoprotein A-I (apoA-I)/HDL into 12 subjects with normal glucose tolerance and 12 patients with noninsulin-dependent diabetes mellitus (NIDDM). The results indicate that the mean fractional catabolic rate (FCR) of apoA-I/HDL was significantly faster [0.63 ± 0.07 (±SEM) vs. 0.39 ± 0.02 I/day; P < 0.001] and the apoA-I/HDL synthetic rate greater (29.4 ± 2.9 vs. 22.9 ± 1.3 mg/kg·day; P < 0.02) in patients with NIDDM than in normal subjects. Furthermore, there were statistically significant inverse relationships between apoA-I/HDL FCR and plasma levels of both HDL cholesterol (r = –0.71; P < 0.001) and apoA-I (r = –0.63; P < 0.001). In addition, the increase in apoA-I/HDL FCR was directly related to fasting plasma glucose (r = 0.78; P < 0.001) and insulin (r = 0.76; P < 0.001) concentrations. These data support the view that the decrease in plasma HDL cholesterol and apoA-I levels commonly found in patients with noninsulin-dependent diabetes i s due to an increase in the catabolic rate of apoA-I/HDL secondary to the defects in carbohydrate metabolism present in these patients. {J Clin Endocrinol Metab 65: 512, 1987)

^* This work was supported by grants from the NIH (HL-08506 and RR-7022).

Forgarty International Research Fellow.

Exchange Scholar, Beijing Medical College, Beijing, People's Republic of China.

Received February 3, 1987.

This article has been cited by other articles:

				B. Verges, E. Florentin, S. Baillot-Rudoni, J.-M. Petit, M. C. Brindisi, J.-P. Pais de Barros, L. Lagrost, P. Gambert, and L. Duvillard Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes J. Lipid Res., June 1, 2009; 50(6): 1209 - 1215. [Abstract] [Full Text] [PDF]

				B. W. McCrindle, E. M. Urbina, B. A. Dennison, M. S. Jacobson, J. Steinberger, A. P. Rocchini, L. L. Hayman, and S. R. Daniels Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing Circulation, April 10, 2007; 115(14): 1948 - 1967. [Abstract] [Full Text] [PDF]

				R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]

				G. M Reaven The metabolic syndrome: is this diagnosis necessary? Am. J. Clinical Nutrition, June 1, 2006; 83(6): 1237 - 1247. [Abstract] [Full Text] [PDF]

				H. N. Ginsberg REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 383 - 392. [Abstract] [Full Text] [PDF]

				J. Steinberger and S. R. Daniels Obesity, Insulin Resistance, Diabetes, and Cardiovascular Risk in Children: An American Heart Association Scientific Statement From the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism) Circulation, March 18, 2003; 107(10): 1448 - 1453. [Full Text] [PDF]

				C. M. Hoehner, K. J. Greenlund, S. Rith-Najarian, M. L. Casper, and W. M. McClellan Association of the Insulin Resistance Syndrome and Microalbuminuria among Nondiabetic Native Americans.The Inter-Tribal Heart Project J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1626 - 1634. [Abstract] [Full Text] [PDF]

				J. McEneny, C. McMaster, E. R. Trimble, and I. S. Young Rapid isolation of VLDL subfractions: assessment of composition and susceptibility to copper-mediated oxidation J. Lipid Res., May 1, 2002; 43(5): 824 - 831. [Abstract] [Full Text] [PDF]

				R. Frénais, H. Nazih, K. Ouguerram, C. Maugeais, Y. Zaïr, J. M. Bard, B. Charbonnel, T. Magot, and M. Krempf In Vivo Evidence for the Role of Lipoprotein Lipase Activity in the Regulation of Apolipoprotein AI Metabolism: A Kinetic Study in Control Subjects and Patients with Type II Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1962 - 1967. [Abstract] [Full Text]